Having trouble viewing this in your email? Click here to see it in a browser

Upcoming Events week of March 20- March 26

March 22

CCB Seminar – 12P, 201 Erma Byrd

Tumor heterogeneity in lung cancer – impact on treatment response and resistence emergence

Zuan-Fu Lim, PhD candidate

WVU Cancer Institute Director Dr. Richard Goldberg shares his thoughts on the Cancer Institute’s missions


New WVU Cancer Institute Director Rich Goldberg, MD, says seeking NCI designation is an important goal that the Cancer Institute should strive for, but the end shouldn’t be NCI designation; it should be an incredibly challenging and vibrant intellectual community, an incredibly good caregiver community and a community that educates the next generation of scientists. Dr. Goldberg shared his thoughts and hopes for the Cancer Institute with faculty, staff and students during an open forum at the Health Sciences Center this past Wednesday.

Click here if you missed the forum


Official WVU pink t-shirts available


If you missed the chance to get an official flying WV pink t-shirt during  WVU Athletic’s pink games, you are in luck.  For a $10 donation you can get a t-shirt at the Cancer Institute Office of Philanthropy.  Ask for Tina Lankford (Room 1834).  Please bring the exact amount of cash.  Checks will also be accepted.  Questions?


Cancer Institute partner clinics raise colorectal cancer awareness

Our West Virginia Program to Increase Colorectal Cancer Screening (WV PICCS) partner clinics participated in national Dress in Blue Day on Friday, March 3. Dress in Blue Day began as a way to present a united front in the battle against the disease during Colorectal Cancer Awareness Month. Partner clinic staff donned their favorite shade a blue in order to raise awareness of colorectal cancer screening with their patients. 
Read More


Science advocate, author to speak at WVU


Dr. Paul Offit’s lecture on Friday, March 24 in Patteson Auditorium will include tales from his upcoming book, “Pandora’s Lab,” that discusses seven instances where scientists failed spectacularly – and how, in many instances, these missteps can pave the way for new, unintended discoveries. The lecture is the highlight of WVU’s annual two-day Van Liere Research Days celebration.


WVCTSI to host SOCRA Clinical Research Professional certification exam.
WVCTSI will serve as host site for the Clinical Research Professional certification exam, offered by the Society of Clinical Research Associates(SOCRA). The exam will be offered at the West Virginia University Health Sciences Center in Morgantown on May 25, 2017, from 1 p.m. to 5 p.m.  The deadline for exam registration is April 13.

WVCTSI will also host a series of weekly informational sessions to help prepare those interested in taking the exam. Prep courses will be offered April 6, April 13, April 20, April 28, May 4, May 11, and May 18 from 12 p.m. to 1:30 p.m. in room 301 of the Erma Byrd Biomedical Research Building.
Learn more about the exam and prep courses.


New lung cancer survivorship program featured on Cancer Institute website

The WVU Cancer Institute’s Program, “Bridge to Good Living: Thriving beyond Lung Cancer,” is designed to provide interdisciplinary, patient- centered survivor care services to all lung cancer patients who complete active treatment.
More details


Dr. Paul Lockman named 2016 Benedum Distinguished Scholar

Paul Lockman, PhD, BSN, the Douglas Glover Chair of Pharmaceutical Sciences & Associate Director for Translational Research at the WVU Cancer Institute, has been named a 2016 Benedum Distinguished Scholar. The Distinguished Scholars awards are given to exceptional faculty members at WVU in recognition of the high caliber of their research and scholarly activity.
Read more


WVU Cancer Institute sponsorship of Relay for Life announced in new video


A new video lists the WVU Cancer Institute as the presenting sponsor of this year’s Monongalia County Relay for Life and features several WVU Medicine folks. The Relay is scheduled for Friday and Saturday, June 9-10, at Westwood Middle School in Morgantown.
Watch the video


2017 WV Bio Summit to include Life Science Research Showcase

The Bioscience Association of West Virginia will host the 7th Annual West Virginia Bioscience Summit beginning at 10:30A on April 25, 2017 at the Waterfront Place Hotel in Morgantown. The event will bring together biotech companies, academic researchers, service providers, policy makers, economic developers, funders and others to engage in a day of education and inspiration that will include a Life Science Research Showcase at 5P. The showcase is open to all WV companies, academicians, and clinicians who are interested in presenting the work they are doing to improve human health. Participants in the showcase are encouraged to be creative in the way they present research or company products. A standard quad poster presentation as well as other approaches such as an interactive demonstration are welcome.

Dr. George Bennett, CEO of Good Measures, a Boston based firm, who is pioneering a data-driven approach to personal nutrition, will be the keynote speaker. Other notable speakers include WVU President Gee, along with Vice President & Executive Dean for Health Sciences, Dr. Clay Marsh. More details or To register contact Debra Beery


Talk with Tony, part of activities at the WVU Cancer Institute’s 32nd Annual Spring Gala

Come be a part of an event that saves lives! Register now for the WVU Cancer Institute 32nd Annual Spring Gala at The Greenbrier Resort in White Sulphur Springs, West Virginia, April 28-30. Among the wide variety of activities and entertainment on tap during the weekend-long signature event is a Talk with Tony session hosted by WVU sports broadcaster Tony Caridi focusing on several hot topics sure to please Mountaineer fans.
Read more


Learn about the latest actions and activities of the WV Legislature in the March 13 issue of Under the Dome.

Lewis County family taking proactive approach against colon cancer – WDTV

Gordon Gee: Celebrate WVU’s legacy by imagining the state’s future – Charleston Gazette-Mail

News from Athletics

2017 football season tickets now on sale

Volleyball announces summer camp dates

Gratz wins Elite 90 Award

Mountaineers collect 14 All-America Awards

Morehead state game rescheduled for April 5

Another Year, Another NCAA Tournament for Huggs

IMG NCAA Tournament guide

Thrasher finalist for 87th AAU Award

Seven earn Academic All-Big 12 honors

Huggins Wins $15,000 for Cancer Research – Keyser Mineral Daily News-Tribune

Concept of phase cycling in pulsed magnetic resonance using sinusoidal magnetic field modulation.
Tseytlin MP. Z Phys Chem. 2017;231(3):689-703.
Read More

Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells.
He X, Wang LY, Riedel H, Wang K, Yang Y, Dinu CZ, Rojanasakul Y. Mol Cancer. 2017;16(1):63.
Read More

Attitudes of radiation oncologists toward palliative and supportive care in the United States: Report on national membership survey by the American Society for Radiation Oncology (ASTRO).
Wei RL, Mattes MD, Yu J, Thrasher A, Shu HK, Paganetti H, De Los Santos J, Koontz B, Abraham C, Balboni T. Pract Radiat Oncol. 2017;7(2):113-119.
Read More

Federal Grants and Opportunities

U.S. Tobacco Control Policies to Reduce Health Disparities (R01) - PAR-17-217
Organization: NCI 
Summary: The purpose of this Funding Opportunity Announcement (FOA) is to support observational or intervention research focused on reducing health disparities in tobacco use in the United States. Specifically, this FOA is intended to stimulate scientific inquiry focused on innovative tobacco control policies including, but not limited to, those addressing health economics (e.g. tax and pricing policies, insurance coverage for tobacco dependence treatment). Applicants may propose projects in which the primary outcome of interest is on reducing tobacco use health disparities in vulnerable populations by utilizing tobacco prevention and control strategies. The long-term goal of this FOA is to reduce health disparities in health outcomes thereby reducing the excess disease burden of tobacco use within these groups. This FOA provides funding for up to 2-years for research planning, intervention delivery, dissemination and implementation. Applicants submitting proposals related to health economics are encouraged to consult NOT-OD-16-025 to ensure that proposals align with NIH mission priorities in health economics research 

U.S. Tobacco Control Policies to Reduce Health Disparities (R21) - PAR-17-218
Organization: NCI 
Summary: The purpose of this Funding Opportunity Announcement (FOA) is to support observational or intervention research focused on reducing health disparities in tobacco use in the United States. Specifically, this FOA is intended to stimulate scientific inquiry focused on innovative tobacco control policies including, but not limited to, those addressing health economics (e.g. tax and pricing policies, insurance coverage for tobacco dependence treatment). Applicants may propose projects in which the primary outcome of interest is on reducing tobacco use health disparities in vulnerable populations by utilizing tobacco prevention and control strategies. The long-term goal of this FOA is to reduce health disparities in health outcomes thereby reducing the excess disease burden of tobacco use within these groups. This FOA provides funding for up to 2-years for research planning, intervention delivery, dissemination and implementation. Applicants submitting proposals related to health economics are encouraged to consult NOT-OD-16-025 to ensure that proposals align with NIH mission priorities in health economics research. 

Revision Applications to National Cancer Institute (NCI)-supported U01 Awards to Include Research on the NCI's Provocative Questions (U01) - RFA-CA-17-020
Organization: NCI 
Summary: This Funding Opportunity Announcement (FOA) invites revision applications from investigators with active NCI U01 research project awards. These revision applications are expected to focus on research related to one of the 12 of the NCI's Provocative Questions (PQs) published for new applications in RFA-CA-17-017 (R01) and RFA-CA-17-018 (R21). This FOA encourages research that directly addresses PQs, including research that helps validate PQ research outcomes or adopt and disseminate PQ research results that impact cancer research and clinical care. Studies proposed in the revision applications must correspond to additional specific aims, expanding the scope of individual, already funded projects of the parent U01 award.  

Revision Applications to National Cancer Institute (NCI)-supported P01 Awards to Include Research on the NCI's Provocative Questions (P01) - RFA-CA-17-021
Organization: NCI 
Summary: Projects. These revision applications are expected to focus on research related to one of the 12 of the NCI's Provocative Questions (PQs) published in RFA-CA-17-017 and RFA-CA-17-018 that are intended for new R01 and R21 applications, respectively. This FOA encourages research that directly addresses PQs, including research that helps validate PQ research outcomes or adopt and disseminate PQ research results that impact cancer research and clinical care. Studies proposed in the revision applications must correspond to a new research project expanding the scope, yet integrated into the overall theme, of the entire parent P01 award.  

Revision Applications to National Cancer Institute (NCI)-supported P50 Awards to Include Research on the NCI's Provocative Questions (P50) - RFA-CA-17-022
Organization: NCI 
Summary: This Funding Opportunity Announcement (FOA) invites revision applications from currently funded NCI P50 Specialized Centers. These revision applications are expected to focus on research related to one of the 12 of the NCI's Provocative Questions (PQs) published in RFA-CA-17-017 and RFA-CA-17-018 that are intended for new R01 and R21 applications, respectively. This FOA encourages research that directly addresses PQs, including research that helps validate PQ research outcomes or adopt and disseminate PQ research results that impact cancer research and clinical care. Studies proposed in the revision applications must correspond to a new research project expanding the scope, yet integrated into the overall theme, of the entire parent P50 award.  

Revision Applications to NCI-supported R01 Awards to Include Research on the NCI's Provocative Questions (R01) - RFA-CA-17-019
Organization: NCI 
Summary: This Funding Opportunity Announcement (FOA) invites revision applications from investigators with active NCI R01 research grants. These revision applications are expected to focus on research related to one of the 12 of the NCI's Provocative Questions (PQs) published for new applications in RFA-CA-17-017 (R01) and RFA-CA-17-018 (R21). This FOA encourages research that directly addresses PQs, including research that helps validate PQ research outcomes or adopt and disseminate PQ research results that impact cancer research and clinical care. Studies proposed in the revision applications must correspond to additional specific aims, expanding the scope of individual, already funded projects of the parent R01 award.  

Supplements for Validating the Use of Automated Sources of Residential Histories in Cancer Epidemiology Cohorts (Admin Supp) - PA-17-222
Organization: NCI 
Summary: The National Cancer Institute (NCI) announces an opportunity for awardees holding eligible NCI-funded awards to request administrative supplement funding to support augmented efforts to refine automated methodologies to obtain more accurate and reliable lifetime residential history data and linkages that would enhance cancer research.  

Research Supplements to Promote Sharing Data in Cancer Epidemiology Studies (Admin Supp) - PA-17-224
Organization: NCI 
Summary: The National Cancer Institute (NCI) hereby notifies Program Director(s)/Principal Investigator(s) holding eligible awards (as specified in this FOA) that funds are available for administrative supplements to prepare and deposit individual-level data from cancer epidemiology studies into NCI-supported, controlled-access databases including the Cancer Epidemiology Data Repository (CEDR) and the database of Genotypes and Phenotypes (dbGaP). Sharing of research data will accelerate scientific discovery and increase opportunities for collaboration to provide new clues to cancer etiology, determine risk factors, and improve cancer survivorship.  

Supplement Opportunity to Support Population-Based Research Studies of Rare Cancers (Admin Supp) - PA-17-223
Organization: NCI 
Summary: Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) invites applications for supplemental funding to eligible NCI awards so that involved personnel (awardees) can advance their efforts to gain needed knowledge on rare cancers. The goal is to support population-based, hypothesis-testing studies that will increase our understanding of the etiology or post-diagnosis outcomes of rare cancers.  

Mechanisms of Alcohol-associated Cancers (R01) - PA-17-220
Organization: NIAAA 
Summary: This Funding Opportunity Announcement (FOA) invites applications investigating the cellular and molecular mechanisms by which alcohol increases cancer risk. Alcohol consumption is classified as carcinogenic to humans by the International Agency for Research on Cancer (IARC; 2010, 2012) and the National Toxicology Program (NTP; 2014) of the US Department of Health and Human Services. Target sites for alcohol-related carcinogenesis include the upper aerodigestive tract, breast, liver, and colon. A better understanding of the molecular basis by which alcohol increases cancer risk for certain tissues and organs could lead to improved therapeutic approaches and preventative strategies and would provide guidance on safe levels of alcohol consumption. 

Mechanisms of Alcohol-associated Cancers (R21) - PA-17-219
Organization: NIAAA 
Summary: This Funding Opportunity Announcement (FOA) invites applications investigating the cellular and molecular mechanisms by which alcohol increases cancer risk. Alcohol consumption is classified as carcinogenic to humans by the International Agency for Research on Cancer (IARC; 2010, 2012) and the National Toxicology Program (NTP; 2014) of the US Department of Health and Human Services. Target sites for alcohol-related carcinogenesis include the upper aerodigestive tract, breast, liver, and colon. A better understanding of the molecular basis by which alcohol increases cancer risk for certain tissues and organs could lead to improved therapeutic approaches and preventative strategies and would provide guidance on safe levels of alcohol consumption.  

Enhancing Science, Technology, EnginEering, and Math Educational Diversity (ESTEEMED) Research Education Experiences (R25) - PAR-17-221
Organization: NIBIB 
Summary: The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this National Institute of Biomedical Imaging and Bioengineering (NIBIB) R25 program is to support educational activities that enhance the diversity of the biomedical, behavioral and clinical research workforce.  

Pragmatic Research in Healthcare Settings to improve Kidney Disease Prevention and Care (R18) - RFA-DK-17-008
Organization: NIDDK 
Summary: The purpose of this Research Demonstration and Dissemination Projects (R18) Funding Opportunity Announcement (FOA) is to encourage research applications to test approaches to improve kidney disease prevention and/or treatment in routine healthcare settings. Research applications should be designed to test practical and potentially sustainable strategies that target the prevention or improved care of kidney disease, or the prevention or delay of the complications of kidney disease. The goal of the research is to obtain results that will improve routine healthcare practice and inform healthcare policy for the prevention or management of these conditions. 

Tobacco Centers of Regulatory Science for Research Relevant to the Family Smoking Prevention and Tobacco Control Act (U54) - RFA-OD-17-003
Organization: NIH 
Summary: The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for Tobacco Centers of Regulatory Science (TCORS) to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). The awards under this FOA will be administered by NIH using funds that have been made available through FDA CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health. 

Center for Coordination of Analytics, Science, Enhancement , and Logistics (CASEL) in Tobacco Regulatory Science (U54) - RFA-OD-17-002
Organization: NIH 
Summary: This Funding Opportunity Announcement (FOA) solicits applications for a Center for Coordination of Analytics, Science, Enhancement, and Logistics (CASEL) in Tobacco Regulatory Science. CASEL will support the scientific research programs funded by the Food and Drug Administration (FDA) Center for Tobacco Products (CTP), and will facilitate synthesis, coordination and communications of research and career enhancement within those programs. The overall objective of CASEL is to support research programs that can inform the FDA CTP in tobacco product regulatory activities and actions. Through leadership, coordination, and facilitation of collaborative efforts, CASEL can accelerate the advancement of science relevant to the Family Smoking Prevention and Tobacco Control Act (FSPTCA). The NIH and the FDA have formed an interagency partnership to foster research relevant to FDA's tobacco regulatory authorities. The award under this FOA will be administered by the NIH using designated funds from the FDA CTP for tobacco regulatory science mandated by the Family Smoking Prevention and Tobacco Control Act (FSPTCA), Public Law 111-31. 

NIH Notices

Other Funding or Opportunities

Nancy Sanders Memorial Student And Faculty Travel And Research Abroad Grants Open To Submissions

In honor of the legacy of long-time staff member in WVU’s Global Health Program, the Global Engagement Office (GEO) at Health Sciences is pleased to announce that the application period for the Nancy Sanders Memorial Student Travel Grant and the Nancy Sanders Memorial Faculty Research Abroad Grant is now open. Applicant eligibility, program details, and application instructions can be found on the GEO webpage. The deadline for submission for both grant awards is Friday, March 31. For more information, contact Carrie Waybright, HSC GEO Program Specialist, at cwaybrig@hsc.wvu.edu.

March 27

HSC Interprofessional Education Week celebration- Various times/locations at HSC
For more information

March 29

Meeting of the Minds: Appalachian Poverty – 4-6P,

Erickson Alumni Center, Salon A-B
RSVP to Rick Remish by March 20
Sponsored by the Mountaineer Health Initiative: Mountaineers driving collaborations to improve the health of West Virginians
More details

March 31

Special Seminar – 12-1P, Fukushima Auditorium, presented by WVU Cancer Institute

Expediting Oncology Drug Development in an Era of Breakthrough Therapies

Richard Pazdur, MD
Acting Director
Oncology Center of Excellence
U.S. Food and Drug Administration

April 8

Make The Magic gala fundraiser – 6P, Evansdale Crossing, Morgantown, RSVP at donate.kesem.org/wvumtm
Benefits Camp Kesem at WVU.  Camp Kesem provides children of cancer patients with a free summer camp.

April 12

CCB Spring Seminar Series – 12-1P, HSN Room 2157

Andrew Kossenkov, PhD
Director, Bioinformatics Facility
Center for Systems & Computational Biology
The Wistar Institute

Integrative Approach to Comprehensive Analysis of High Throughput Data on a Cancer Center Level

April 19

CCB Spring Seminar Series – 12-1P, HSN Room 2157

Eugenia Broude, PhD
South Carolina College of Pharmacy
University of South Carolina

CDK8/19: a novel transcriptional target for breast cancer therapy


April 22

Transplant Patient Reunion – 12-2P, Lakeview Resort, Morgantown

April 28-30

2017 WVU Cancer Institute Spring Gala
The Greenbrier, White Sulphur Springs, WV
More details